<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of primary ovarian insufficiency (premature ovarian failure)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of primary ovarian insufficiency (premature ovarian failure)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of primary ovarian insufficiency (premature ovarian failure)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Corrine K Welt, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William F Crowley, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         46,XX primary ovarian insufficiency (POI) is defined as the development of primary hypogonadism before the age of 40 years in women who have a normal karyotype. The presenting symptoms are similar to those of menopause. The age-specific incidence of spontaneous POI is approximately 1 in 250 by age 35 years and 1 in 100 by age 40 years [
         <a href="#rid1">
          1
         </a>
         ]. In its fully developed form, it is associated with oligomenorrhea or amenorrhea, symptoms of estrogen deficiency, and gonadotropin levels in the menopausal range before age 40 years. The terms "premature menopause" and "premature ovarian failure" were used in the past for POI, but both are inaccurate because many patients with spontaneous POI produce estrogen intermittently and ovulate, a few experience intermittent return of regular menses, and, in 5 to 10 percent of cases, women conceive and have a normal pregnancy [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The management of women with POI will be reviewed here. Turner syndrome (45,X0 or other Xp chromosome abnormalities), as well as other aspects of 46,XX POI (including autoimmune POI) are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7443.html" rel="external">
          "Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7414.html" rel="external">
          "Autoimmune primary ovarian insufficiency (premature ovarian failure)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7435.html" rel="external">
          "Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7386.html" rel="external">
          "Management of Turner syndrome in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7443.html" rel="external">
          "Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)", section on 'Introduction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16060474">
         <span class="h1">
          INFORMING THE PATIENT OF THE DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most important steps after making the diagnosis of spontaneous primary ovarian insufficiency (POI) (
         <a class="graphic graphic_algorithm graphicRef131982" href="/z/d/graphic/131982.html" rel="external">
          algorithm 1
         </a>
         ) are to inform the patient of the diagnosis in a sensitive and caring manner, provide accurate information, and offer referral to appropriate resources for emotional support. The most common words women use to describe their emotional state in the immediate hours after receiving the diagnosis are "devastated," "shocked," and "confused" [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Young women with POI are usually unprepared for the diagnosis, and the majority are unhappy with the manner in which they were informed [
         <a href="#rid4">
          4
         </a>
         ]. In one study of 100 women with POI, 71 percent were dissatisfied with how they were informed of their diagnosis [
         <a href="#rid3">
          3
         </a>
         ]. Specific areas of improvement suggested by women in the study included the need for clinicians to spend more time with the patient and provide more information about this condition. The diagnosis of POI brings with it the potential for development of related depression and anxiety disorders [
         <a href="#rid3">
          3,5
         </a>
         ]. It is also important to provide information about the possible cause of the POI, although this is unknown in many cases. The causes of POI are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7435.html" rel="external">
          "Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)"
         </a>
         .)
        </p>
        <p>
         It is best to schedule a return office visit to review the laboratory results when the diagnosis is suspected. Clinicians should inform patients that 50 to 75 percent of women with 46,XX spontaneous POI experience intermittent ovarian function and that 5 to 10 percent of women are able to become pregnant sometime after the diagnosis [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7443.html" rel="external">
          "Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)", section on 'Clinical features'
         </a>
         and
         <a class="local">
          'Fertility'
         </a>
         below.)
        </p>
        <p>
         When first diagnosed with POI, some patients feel a need to act immediately to achieve a pregnancy. It is important to point out that in addition to fertility challenges, other issues need to be addressed, as POI may have adverse effects on long-term health, such as emotional health, autoimmune endocrinopathies, cardiovascular disease, and osteoporosis [
         <a href="#rid6">
          6-11
         </a>
         ]. An increased risk of cognitive dysfunction and dementia may also be a risk, but this is not well established in women with POI not due to bilateral oophorectomy. (See
         <a class="medical medical_review" href="/z/d/html/7443.html" rel="external">
          "Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)", section on 'Consequences of estrogen deficiency'
         </a>
         and
         <a class="local">
          'Emotional health'
         </a>
         below and
         <a class="local">
          'Autoimmune endocrinopathies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1222519042">
         <span class="h1">
          IMPORTANCE OF ESTROGEN THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H3637735459">
         <span class="h2">
          Goals
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unless there is an absolute contraindication to taking estrogen therapy, all women with primary ovarian insufficiency (POI) should receive estrogen therapy to reduce the risk of osteoporosis and cardiovascular disease. In addition, estrogen therapy is important to maintain sexual health and quality of life and to treat genitourinary syndrome of menopause (with vaginal estrogen), if necessary. Our approach is consistent with The American College of Obstetricians and Gynecologists (ACOG) Committee Opinions on POI in adolescents and young women [
         <a href="#rid12">
          12
         </a>
         ] and hormone therapy in POI [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Although exogenous estrogen replacement is recommended, only limited data are available about the advantages or disadvantages of different hormone regimens or about estrogen's efficacy for bone health and cardiovascular disease prevention in women with POI. However, there is abundant indirect evidence from menopausal women that physiologic estrogen doses are bone protective and that the benefits of hormone therapy outweigh the risks for women in their 50s or &lt;10 years since menopause. (See
         <a class="medical medical_review" href="/z/d/html/7443.html" rel="external">
          "Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)", section on 'Cardiovascular morbidity and mortality'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">
          "Treatment of menopausal symptoms with hormone therapy", section on 'Contraindications'
         </a>
         .)
        </p>
        <p>
         Most patients are aware of the association between estrogen deficiency, the risk of osteoporosis, and the need for estrogen therapy. However, some women are initially reluctant to consider estrogen therapy based upon results from the Women's Health Initiative [WHI], a set of hormone therapy trials in postmenopausal females that reported possible risks of cardiovascular complications and breast cancer in older subjects taking hormone therapy [
         <a href="#rid14">
          14
         </a>
         ]. Women should be reassured that the WHI data are not clinically relevant to young women with POI, as they are otherwise healthy and have low baseline risks of both cardiovascular disease and breast cancer. The issue of postmenopausal hormone is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">
          "Menopausal hormone therapy: Benefits and risks"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3440855282">
         <span class="h2">
          Suggested estrogen regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Theoretically, hormone replacement for young women with POI should mimic normal ovarian function as much as possible.
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          Estradiol
         </a>
         (17-beta-estradiol; E2) and micronized
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         are bioidentical hormones, eg, they have the same molecular structure as the estradiol and progesterone produced by the ovary (see
         <a class="medical medical_review" href="/z/d/html/7446.html" rel="external">
          "Preparations for menopausal hormone therapy"
         </a>
         ). Optimal replacement with sex steroids depends on whether the patient presents with primary or secondary amenorrhea.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary amenorrhea
         </strong>
         – Girls or young women with primary amenorrhea in whom secondary sex characteristics have not developed should initially be given very low doses of
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         (at first without a progestin) in an attempt to mimic gradual pubertal maturation. (See
         <a class="medical medical_review" href="/z/d/html/5814.html" rel="external">
          "Approach to the patient with delayed puberty", section on 'Estradiol therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary amenorrhea
         </strong>
         – Most women present with secondary amenorrhea. We initiate full replacement doses of estrogen with oral
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         (2 mg/day) or transdermal estradiol (100 mcg patch). An estradiol vaginal ring (100 mcg daily) is another option [
         <a href="#rid15">
          15-17
         </a>
         ]. This dose is higher than what is used for postmenopausal females and is based upon the average daily production of estradiol by the premenopausal ovary.
        </p>
        <p>
        </p>
        <p>
         Transdermal or vaginal delivery of
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         have advantages over oral estradiol, including lower risks of venous thromboembolism and gallbladder disease [
         <a href="#rid18">
          18,19
         </a>
         ]. However, the advantages related to vascular safety are more important in older, postmenopausal females. Therefore, for those with POI who do not like or do not tolerate transdermal or vaginal estradiol, oral estradiol is perfectly acceptable. Some women prefer to take a combined oral estrogen-progestin contraceptive as described below. (See
         <a class="local">
          'COC as alternative option'
         </a>
         below.)
        </p>
        <p>
         We do not suggest routine monitoring of serum
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         levels [
         <a href="#rid13">
          13
         </a>
         ]. We suggest starting with suggested dosing above and titrating doses to alleviate symptoms or using a lower dose that is adequate to preserve bone density in patients who experience side effects. (See
         <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">
          "Treatment of menopausal symptoms with hormone therapy", section on 'Dose'
         </a>
         .)
        </p>
        <p>
         For women with symptoms suggestive of genitourinary syndrome of menopause (vaginal dryness, urinary symptoms), we suggest adding low-dose vaginal estrogen. Many women with POI, like those with natural or surgical menopause, add low-dose vaginal estrogen, even if they are on systemic estrogen. The use of low-dose vaginal estrogen is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">
          "Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Vaginal estrogen therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2084645239">
         <span class="h2">
          Choice of progestin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most women with POI will have an intact uterus and require a progestin to prevent estrogen-induced endometrial hyperplasia and carcinoma [
         <a href="#rid20">
          20
         </a>
         ]. Our first-line progestin is micronized
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         (MP) 200 mg per day for the first 12 days of the month [
         <a href="#rid17">
          17,21
         </a>
         ].
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          Medroxyprogesterone acetate
         </a>
         (MPA) is used by some clinicians. For MPA, endometrial safety data come from one trial in women with POI [
         <a href="#rid21">
          21
         </a>
         ] and trials in postmenopausal women. For MP, there is indirect evidence of endometrial protection from multiple trials in postmenopausal women. For women who are unable to tolerate standard progestins, another option is
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         therapy combined with a levonorgestrel-releasing intrauterine device (IUD). For women who desire treatment for estrogen deficiency symptoms, but want to maintain the possibility of a spontaneous conception, only micronized progesterone should be used. (See
         <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">
          "Treatment of menopausal symptoms with hormone therapy", section on 'Progestins'
         </a>
         .)
        </p>
        <p>
         Of note, there are no data comparing the effects of the transdermal estradiol-MP regimen described above with the many other hormone regimens on symptom relief, prevention of bone loss (and other diseases), quality of life, and/or sexual function. However, indirect evidence from trials in postmenopausal women suggest that there are a number of advantages to MP over MPA (no adverse effects on lipids or clotting factors), but this has not yet been studied in the POI population. (See
         <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">
          "Treatment of menopausal symptoms with hormone therapy", section on 'Progestins'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H374586229">
         <span class="h2">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with ACOG, which recommends systemic hormone therapy until age 50 to 51 years to all women with POI (without contraindications) to manage estrogen deficiency symptoms, prevent long-term health risks associated with POI (osteoporosis, coronary heart disease, stroke), improve quality of life, and maintain sexual function (some women may need vaginal estrogen in addition to systemic estrogen). They suggest hormonal contraception options for those in whom pregnancy prevention is a priority. (See
         <a class="local">
          'Contraception'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3502682844">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is abundant indirect evidence from postmenopausal women that hormone therapy would be effective for estrogen deficiency symptoms and bone health in women with POI. While observational data suggest that early natural menopause (prior to age 44, but not POI) is associated with an increase in cardiovascular disease, data on the role of hormone therapy for cardiovascular health in women with POI are lacking. That said, we agree with ACOG that women with POI should receive estrogen therapy unless there is an absolute contraindication [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="local">
          'Importance of estrogen therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">
          "Treatment of menopausal symptoms with hormone therapy", section on 'Contraindications'
         </a>
         .)
        </p>
        <p>
         In a systematic review and meta-analysis of 12 studies (four trials and eight cohort studies) in 806 women with POI, evidence to support bone and cardiovascular benefits of hormone therapy was limited by the use of surrogate outcomes, and heterogeneity between studies in the estrogen dose, route, and regimen) [
         <a href="#rid22">
          22
         </a>
         ]. Two studies suggest that women with POI have significant vascular endothelial dysfunction, which is restored to normal by estrogen therapy [
         <a href="#rid7">
          7,9
         </a>
         ].
        </p>
        <p>
         In addition to estrogen therapy for prevention of bone loss, other important measures for bone health should be emphasized, including exercise, a healthy diet, adequate calcium and vitamin D intake, and avoiding smoking. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H306672520">
         <span class="h2">
          COC as alternative option
         </span>
         <span class="headingEndMark">
          —
         </span>
         A combined estrogen-progestin oral contraceptive pill (COC) containing ethinyl
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         and a progestin is an alternative option, which has the added advantage of providing contraception should spontaneous ovarian activity resume (see
         <a class="local">
          'Contraception'
         </a>
         below). Of note, however, one small trial suggested that lower-dose, physiologic hormone therapy may be more beneficial for bone mineral density than higher-dose estrogen (an oral estrogen-progestin contraceptive) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Standard postmenopausal hormone therapy, which has a much lower dose of estrogen than combined estrogen-progestin contraceptives, does
         <strong>
          not
         </strong>
         provide effective contraception. Since spontaneous ovarian activity may resume, some form of contraception may be required if the patient is not seeking pregnancy. (See
         <a class="local">
          'Contraception'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H617422087">
         <span class="h1">
          FERTILITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 75 percent of women with 46,XX spontaneous primary ovarian insufficiency (POI) have potentially functional follicles remaining in the ovary. Histologic and endocrinologic evidence supports a conclusion that inappropriate follicle luteinization is the most common pathophysiologic mechanism that prevents ovulation and pregnancy in these women [
         <a href="#rid24">
          24,25
         </a>
         ]. (See
         <a class="local">
          'Spontaneous ovulation'
         </a>
         below.)
        </p>
        <p>
         Although some women conceive without treatment, pregnancy rates are very low (5 to 10 percent) [
         <a href="#rid2">
          2,4,26
         </a>
         ]. Options for pregnancy include in vitro fertilization (IVF) with oocyte donation, embryo donation, and adoption (see
         <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">
          "In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'
         </a>
         ). Some women do undergo ovulation induction with
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate and/or exogenous gonadotropins, but we suggest against this approach as neither has been shown to be effective. Adding adjuvant medications to enhance ovulation does not improve pregnancy rates. (See
         <a class="local">
          'Spontaneous ovulation'
         </a>
         below and
         <a class="local">
          'Ineffective or unproven medical therapies'
         </a>
         below.)
        </p>
        <p>
         Women will often ask about the possibility of oocyte cryopreservation at the time of impending or diagnosed POI. Oocyte cryopreservation may be indicated in women with known genetic risk for POI before ovarian function declines (fragile X messenger ribonucleoprotein 1 [
         <em>
          FMR1
         </em>
         ] premutations, Turner mosaic, known autoimmune polyglandular syndrome type 2), but it is less likely to be useful at the time of the POI diagnosis based on the paucity of oocytes left in the ovary [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1857308447">
         <span class="h2">
          Spontaneous ovulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In ultrasound studies of women with POI, follicular development occurs frequently, with evidence of follicle luteinization in many cases. Ovulation is infrequent, with approximately a 4 percent chance per month [
         <a href="#rid24">
          24,28
         </a>
         ]. Small studies suggest frequent monitoring (every two to four weeks) for spontaneous follicle growth by ultrasound may provide an opportunity for a spontaneous conception [
         <a href="#rid28">
          28
         </a>
         ]. Such an approach may also help provide closure should there be no ovarian activity documented in a three- to six-month timeframe. (See
         <a class="medical medical_review" href="/z/d/html/7443.html" rel="external">
          "Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         These spontaneous pregnancies progress entirely normally in most cases, and there appears to be no need for exogenous hormone supplementation during pregnancy.
        </p>
        <p>
         It has been thought that the use of exogenous estrogen therapy might improve follicle function and therefore ovulatory rates [
         <a href="#rid29">
          29
         </a>
         ]. However, in a trial of 37 women with POI receiving oral
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         (2 mg/day) or no therapy for six weeks in a 12-week crossover design, estrogen did not appear to improve mean ovarian volume, the number or size of new follicles, or ovulatory rates [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H196123236">
         <span class="h2">
          Oocyte donation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with POI due to any cause are potential candidates for IVF with donor oocytes. In one report of 61 women with POI undergoing 90 treatment cycles, the cumulative chance of pregnancy after three cycles was approximately 90 percent [
         <a href="#rid30">
          30
         </a>
         ]. Success rates for this procedure depend primarily on the age of the oocyte donor. Women with Turner syndrome require careful cardiovascular evaluation before being considered for this therapy, as deaths from aortic dissection have been reported during pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">
          "In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116877.html" rel="external">
          "Management of Turner syndrome in adults", section on 'Management of fertility and pregnancy'
         </a>
         .)
        </p>
        <p>
         Women with POI who become pregnant by oocyte donation may have an increased risk of delivering infants who are small for gestational age and of having pregnancy-induced hypertension and postpartum hemorrhage [
         <a href="#rid31">
          31-33
         </a>
         ], but these findings are controversial [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">
          "In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1791088620">
         <span class="h2">
          Ineffective or unproven medical therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clomiphene
         </strong>
         <strong>
          citrate and
         </strong>
         <strong>
          letrozole
         </strong>
         – An anti-estrogenic agent such as
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate and the aromatase inhibitor
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          letrozole
         </a>
         have not been studied in this population, but they are unlikely to be effective in women who are hypoestrogenic. (See
         <a class="medical medical_review" href="/z/d/html/7400.html" rel="external">
          "Ovulation induction with clomiphene citrate", section on 'Patient selection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gonadotropin therapy
         </strong>
         – Exogenous gonadotropin therapy has been studied as a potential strategy to improve ovulatory rates in women with POI, but it is ineffective [
         <a href="#rid2">
          2,35,36
         </a>
         ]. Exogenous gonadotropins could theoretically exacerbate unrecognized autoimmune ovarian failure [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Suppression of endogenous gonadotropin concentrations with pharmacologic doses of estrogen prior to gonadotropin therapy has been reported to improve ovulatory rates in some [
         <a href="#rid38">
          38,39
         </a>
         ], but not all [
         <a href="#rid35">
          35
         </a>
         ], studies. In the one randomized, placebo-controlled trial available, treatment with 150 mcg ethinyl
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         /day for two weeks before and during stimulation with recombinant follicle-stimulating hormone (FSH), ovulatory rates were significantly higher in the estrogen group (32 percent, 8 of 25 women) when compared with the placebo group (0 of 25 ovulated) [
         <a href="#rid39">
          39
         </a>
         ]. Ovulation only occurred in women whose serum FSH concentrations were suppressed to ≤15 international units/L with estrogen. It is possible the improved ovulation rates in this study were related to suppression of luteinizing hormone (LH) levels and avoidance of inappropriate follicle luteinization [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Suppression of endogenous gonadotropin concentrations with a gonadotropin-releasing hormone (GnRH) agonist prior to gonadotropin therapy does not appear to improve ovulatory rates [
         <a href="#rid35">
          35,40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoid therapy
         </strong>
         – Glucocorticoid therapy for treatment of suspected autoimmune ovarian failure, also unproven, carries the risk of iatrogenic Cushing syndrome and osteonecrosis of the hip requiring joint replacement [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7414.html" rel="external">
          "Autoimmune primary ovarian insufficiency (premature ovarian failure)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H69313109">
         <span class="h1">
          OTHER ISSUES
         </span>
        </p>
        <p class="headingAnchor" id="H1222512186">
         <span class="h2">
          Emotional health
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of primary ovarian insufficiency (POI) is emotionally traumatic for most women because it disrupts their life plans, hopes, and dreams with regard to future pregnancies. Women with POI may develop related depression and anxiety disorders.
        </p>
        <p>
         As with any life-altering diagnosis, women with POI benefit from encouragement and support that helps them to regain a sense of control and confidence [
         <a href="#rid5">
          5,43
         </a>
         ]. Acceptance of this diagnosis is a gradual process, and the patient needs to give herself time and permission to work through these issues. Feelings of intense grief and loss are normal. Discussions about the normal grieving process, the strains that the diagnosis might bring to a relationship, and the importance of open communication can be helpful. For women who experience significant anxiety and/or depression related to the diagnosis, we suggest seeing a therapist with expertise in POI. In some cases, ongoing individual or group counseling is helpful [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Some young women interpret the diagnosis of POI as an indication that they have become a menopausal woman who is "growing old overnight" [
         <a href="#rid43">
          43
         </a>
         ]. Symptoms of estrogen deficiency such as hot flashes and vaginal dryness can be interpreted as signs of premature aging. However, as noted, estrogen therapy can prevent some of the adverse consequences of estrogen deficiency. (See
         <a class="local">
          'Goals'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3949483358">
         <span class="h2">
          Sexual health
         </span>
        </p>
        <p class="headingAnchor" id="H695278201">
         <span class="h3">
          Vaginal estrogen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most women who are taking a full replacement dose of physiologic
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         score within the normal range on a validated measure of sexual function. Only 7 percent score below the second percentile on a composite sexual function score [
         <a href="#rid44">
          44
         </a>
         ]. As a group, however, compared with controls, women with 46,XX POI score adversely with regard to sexual function [
         <a href="#rid44">
          44,45
         </a>
         ]. Low-dose vaginal estrogen therapy is an option for those who are diagnosed with genitourinary syndrome of menopause. (See
         <a class="medical medical_review" href="/z/d/html/5424.html" rel="external">
          "Overview of sexual dysfunction in females: Epidemiology, risk factors, and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">
          "Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Vaginal estrogen therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H69086219">
         <span class="h3">
          Cancer survivors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with POI due to cytotoxic drugs or radiation therapy are often candidates for
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         therapy. However, the decision to treat with estradiol depends upon the type of cancer. As an example, systemic (but not low-dose) vaginal estrogen is contraindicated in women with breast cancer); conversely, estrogen is prescribed for women with Hodgkin lymphoma and ovarian insufficiency to preserve bone health and prevent cardiovascular disease. Like women with other causes of POI, the current approach is to continue estradiol until approximately age 50 years, the average age at natural menopause.
        </p>
        <p class="headingAnchor" id="H3124257129">
         <span class="h3">
          Role of androgen replacement
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest against the routine use of androgen therapy in women with POI. Although women with POI may have some degree of androgen deficiency when compared with young women without ovarian insufficiency, testosterone therapy has not been shown to be beneficial, and it is associated with important side effects.
        </p>
        <p>
         In several studies of women with POI, serum ovarian androgen concentrations (androstenedione and/or testosterone) were lower than age-matched women without ovarian insufficiency, but similar to those seen in older postmenopausal women [
         <a href="#rid46">
          46-48
         </a>
         ]. In contrast, levels of dehydroepiandrosterone sulfate (DHEAS), an adrenal androgen, were normal (although they would be expected to be low in women with coexisting primary adrenal insufficiency).
        </p>
        <p>
         The clinical consequences of this decrease in ovarian androgens and the possible role of androgen therapy in women with POI have not been extensively studied. However, available data suggest that testosterone therapy is not beneficial. In one trial, 128 women with 46,XX POI on estrogen-progestin therapy were randomly assigned to 12 months of transdermal testosterone (150 mcg patch) or placebo [
         <a href="#rid49">
          49
         </a>
         ]. In spite of a significant increase in mean serum total testosterone concentrations in the testosterone group compared with placebo (50 ng/dL and 18 ng/dL at 12 months, respectively), there were no differences in quality of life, self-esteem, or mood symptoms between the two groups. In a second study, the addition of testosterone to three years of estradiol-progestin therapy did not provide added benefit in bone mineral density [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Potential side effects of androgen replacement include hirsutism and acne and, with oral preparations (eg, dehydroepiandrosterone [DHEA]), dyslipidemia. However, in women with autoimmune ovarian failure and coexisting adrenal insufficiency, adrenal androgen therapy with DHEA may be beneficial. A more detailed discussion of androgen production and therapy in women is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7447.html" rel="external">
          "Overview of androgen deficiency and therapy in females"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1222519065">
         <span class="h2">
          Contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with POI should be informed that
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         /
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         replacement therapy regimens do not provide effective contraception. Therefore, since spontaneous ovarian activity may resume, contraception is required for those who are not pursuing pregnancy [
         <a href="#rid13">
          13
         </a>
         ]. Women who are concerned about the possibility of spontaneous ovulation and pregnancy can choose hormonal contraception or a barrier method of contraception [
         <a href="#rid17">
          17,50,51
         </a>
         ]. (See
         <a class="local">
          'COC as alternative option'
         </a>
         above.)
        </p>
        <p>
         ACOG suggests combined oral estrogen-progestin contraceptives. Other contraceptive options include lower, noncontraceptive doses of
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         (to treat estrogen deficiency symptoms and provide protection against future disease) combined with a
         <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">
          levonorgestrel
         </a>
         intrauterine contraceptive device (IUD) or oral
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         0.35 mg/day (a contraceptive dose of progestin).
        </p>
        <p>
         Other contraceptive options are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1025379295">
         <span class="h2">
          Autoimmune endocrinopathies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Young women with POI are at increased risk for developing other autoimmune endocrinopathies including autoimmune adrenal insufficiency, a potentially fatal disorder [
         <a href="#rid52">
          52
         </a>
         ]. If proper screening with adrenal autoantibodies is performed, approximately 3 percent of women with spontaneous POI will be found to have asymptomatic autoimmune adrenal insufficiency (
         <a class="graphic graphic_table graphicRef67520" href="/z/d/graphic/67520.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7443.html" rel="external">
          "Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)", section on 'Test for adrenal autoantibodies'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Women with positive adrenal autoantibodies
         </strong>
         – Even if their adrenal function is found to be normal at initial evaluation, women with positive adrenal antibodies should be followed annually by these tests. The author of this topic does an annual 8 AM serum cortisol. If &lt;15 mcg/L, a corticotropin (ACTH) stimulation test is necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Women with negative adrenal autoantibodies
         </strong>
         – There are no data to inform initial adrenal function assessment and follow-up for patients with negative tests for adrenal autoimmunity. If adrenal autoantibodies are not present in a woman with POI, a reasonable strategy is to test baseline adrenal function at the time of diagnosis, and if normal, repeat the test only if clinical symptoms develop that suggest adrenal insufficiency (ie, increased skin pigmentation, excessive fatigue, orthostatic hypotension, etc). (See
         <a class="medical medical_review" href="/z/d/html/7443.html" rel="external">
          "Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)", section on 'Test for adrenal autoantibodies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoimmune hypothyroidism
         </strong>
         – Young women with spontaneous POI are at increased risk for developing autoimmune hypothyroidism and should therefore have a yearly serum thyroid-stimulating hormone (TSH) measurement [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7443.html" rel="external">
          "Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)", section on 'Other autoimmune evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23531393">
         <span class="h1">
          WOMEN WITH AUTOIMMUNE POI
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of women with autoimmune primary ovarian insufficiency (POI) is the same as for any woman with POI. Management focuses on (see
         <a class="medical medical_review" href="/z/d/html/7414.html" rel="external">
          "Autoimmune primary ovarian insufficiency (premature ovarian failure)"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consequences of estrogen deficiency (vasomotor symptoms, vaginal atrophy, osteoporosis, and a possible increased risk of coronary heart disease and stroke if not treated with estrogen)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Emotional health/psychosocial support
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contraception and fertility, which is dramatically reduced
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation for other autoimmune disorders (
         <a class="graphic graphic_table graphicRef67520" href="/z/d/graphic/67520.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3253759421">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113774.html" rel="external">
          "Society guideline links: Primary ovarian insufficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15606.html" rel="external">
          "Patient education: Primary ovarian insufficiency (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2176.html" rel="external">
          "Patient education: Primary ovarian insufficiency (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Informing the patient
         </strong>
         – The management of women with spontaneous primary ovarian insufficiency (POI) begins with informing the patient of the diagnosis in a sensitive and caring manner, providing accurate information about the diagnosis, and referring women with the condition to appropriate resources for emotional support (
         <a class="graphic graphic_algorithm graphicRef131982" href="/z/d/graphic/131982.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Young women with this disorder are unprepared for the diagnosis, and unfortunately, most are dissatisfied with the manner in which their health care providers delivered the information. (See
         <a class="local">
          'Informing the patient of the diagnosis'
         </a>
         above and
         <a class="local">
          'Emotional health'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estrogen therapy
         </strong>
         – Unless there is an absolute contraindication to taking estrogen therapy, we suggest
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         for women with POI (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) to reduce the risk of osteoporosis, cardiovascular disease, and urogenital atrophy and to maintain sexual health and quality of life. A progestin needs to be added for those with an intact uterus. (See
         <a class="local">
          'Importance of estrogen therapy'
         </a>
         above and
         <a class="local">
          'Choice of progestin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Duration of therapy
         </strong>
         – We suggest that estrogen therapy be continued at least until approximately age 50 to 51 years, the average age of natural menopause (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Importance of estrogen therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Estrogen-progestin contraception
         </strong>
         – Estrogen-progestin contraception is an alternative way to provide estrogen for women in whom pregnancy prevention is a priority. (See
         <a class="local">
          'Suggested estrogen regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infertility
         </strong>
         – For the anovulatory infertility associated with POI, we suggest not using ovulation induction drugs as they have no proven benefit (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In vitro fertilization (IVF) with donor oocytes or donor embryos, given the high success rates, may be an option. (See
         <a class="local">
          'Fertility'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring for hypothyroidism
         </strong>
         – Young women with spontaneous POI are at increased risk for developing autoimmune hypothyroidism and should therefore have a yearly serum thyroid-stimulating hormone (TSH) measured. (See
         <a class="local">
          'Autoimmune endocrinopathies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Women with autoimmune oophoritis
         </strong>
         – Women with positive adrenal antibodies but normal adrenal function at the initial evaluation (corticotropin [ACTH] stimulation test) should be retested annually. The author of this topic performs an annual 8 AM serum cortisol. If serum cortisol is &lt;15 mcg/L, an
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         should be performed. If adrenal autoantibodies are not present in a woman with POI, a reasonable strategy is to test baseline adrenal function at the time of diagnosis, and if normal, repeat the test only if clinical symptoms develop that suggest adrenal insufficiency (ie, increased skin pigmentation, excessive fatigue, orthostatic hypotension, etc). (See
         <a class="medical medical_review" href="/z/d/html/7414.html" rel="external">
          "Autoimmune primary ovarian insufficiency (premature ovarian failure)", section on 'Additional autoimmune evaluation after diagnosis'
         </a>
         and
         <a class="local">
          'Autoimmune endocrinopathies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Turner syndrome
         </strong>
         – The management of women with Turner syndrome (45,X0) is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7386.html" rel="external">
          "Management of Turner syndrome in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3780125370">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Lawrence M Nelson, MD, and Karim Calis, PharmD, MPH, FASHP, FCCP, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986; 67:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999; 5:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groff AA, Covington SN, Halverson LR, et al. Assessing the emotional needs of women with spontaneous premature ovarian failure. Fertil Steril 2005; 83:1734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alzubaidi NH, Chapin HL, Vanderhoof VH, et al. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol 2002; 99:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orshan SA, Furniss KK, Forst C, Santoro N. The lived experience of premature ovarian failure. J Obstet Gynecol Neonatal Nurs 2001; 30:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalantaridou SN, Naka KK, Papanikolaou E, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004; 89:3907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005; 162:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostberg JE, Storry C, Donald AE, et al. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism. Clin Endocrinol (Oxf) 2007; 66:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007; 69:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, estrogen, and dementia: a 2014 update. Mol Cell Endocrinol 2014; 389:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol 2014; 124:193. Reaffirmed 2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency. Obstet Gynecol 2017; 129:e134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalantaridou SN, Nelson LM. Premature ovarian failure is not premature menopause. Ann N Y Acad Sci 2000; 900:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009; 360:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA 2005; 293:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996; 275:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 2014; 99:3418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgos N, Cintron D, Latortue-Albino P, et al. Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review. Endocrine 2017; 58:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crofton PM, Evans N, Bath LE, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol (Oxf) 2010; 73:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson LM, Anasti JN, Kimzey LM, et al. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab 1994; 79:1470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubayter ZR, Popat V, Vanderhoof VH, et al. A prospective evaluation of antral follicle function in women with 46,XX spontaneous primary ovarian insufficiency. Fertil Steril 2010; 94:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril 2005; 83:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez F, International Society for Fertility Preservation–ESHRE–ASRM Expert Working Group. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives. Fertil Steril 2017; 108:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor AE, Adams JM, Mulder JE, et al. A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea. J Clin Endocrinol Metab 1996; 81:3615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popat VB, Vanderhoof VH, Calis KA, et al. Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency. Fertil Steril 2008; 89:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paulson RJ, Hatch IE, Lobo RA, Sauer MV. Cumulative conception and live birth rates after oocyte donation: implications regarding endometrial receptivity. Hum Reprod 1997; 12:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdalla HI, Billett A, Kan AK, et al. Obstetric outcome in 232 ovum donation pregnancies. Br J Obstet Gynaecol 1998; 105:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Söderström-Anttila V, Tiitinen A, Foudila T, Hovatta O. Obstetric and perinatal outcome after oocyte donation: comparison with in-vitro fertilization pregnancies. Hum Reprod 1998; 13:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salha O, Sharma V, Dada T, et al. The influence of donated gametes on the incidence of hypertensive disorders of pregnancy. Hum Reprod 1999; 14:2268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krieg SA, Henne MB, Westphal LM. Obstetric outcomes in donor oocyte pregnancies compared with advanced maternal age in in vitro fertilization pregnancies. Fertil Steril 2008; 90:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surrey ES, Cedars MI. The effect of gonadotropin suppression on the induction of ovulation in premature ovarian failure patients. Fertil Steril 1989; 52:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Awwad J, Farra C, Hannoun A, et al. Idiopathic premature ovarian failure: what is the most suitable ovarian stimulation protocol? Clin Exp Obstet Gynecol 2013; 40:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tidey GF, Nelson LM, Phillips TM, Stillman RJ. Gonadotropins enhance HLA-DR antigen expression in human granulosa cells. Am J Obstet Gynecol 1992; 167:1768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Check JH, Nowroozi K, Chase JS, et al. Ovulation induction and pregnancies in 100 consecutive women with hypergonadotropic amenorrhea. Fertil Steril 1990; 53:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tartagni M, Cicinelli E, De Pergola G, et al. Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. Fertil Steril 2007; 87:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen GF, Stone SC, Yee B. Ovulation induction in women with premature ovarian failure: a prospective, crossover study. Fertil Steril 1992; 57:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Kasteren YM, Hoek A, Schoemaker J. Ovulation induction in premature ovarian failure: a placebo-controlled randomized trial combining pituitary suppression with gonadotropin stimulation. Fertil Steril 1995; 64:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalantaridou SN, Braddock DT, Patronas NJ, Nelson LM. Treatment of autoimmune premature ovarian failure. Hum Reprod 1999; 14:1777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson LM. Spontaneous premature ovarian failure: young women, special needs. Menopause Management 2001; 10:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalantaridou SN, Vanderhoof VH, Calis KA, et al. Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency. Fertil Steril 2008; 90:1805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause 2011; 18:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernardi F, Hartmann B, Casarosa E, et al. High levels of serum allopregnanolone in women with premature ovarian failure. Gynecol Endocrinol 1998; 12:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachelot A, Meduri G, Massin N, et al. Ovarian steroidogenesis and serum androgen levels in patients with premature ovarian failure. J Clin Endocrinol Metab 2005; 90:2391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elias AN, Pandian MR, Rojas FJ. Serum levels of androstenedione, testosterone and dehydroepiandrosterone sulfate in patients with premature ovarian failure to age-matched menstruating controls. Gynecol Obstet Invest 1997; 43:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerrieri GM, Martinez PE, Klug SP, et al. Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause 2014; 21:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panay N, Kalu E. Management of premature ovarian failure. Best Pract Res Clin Obstet Gynaecol 2009; 23:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goswami D, Conway GS. Premature ovarian failure. Horm Res 2007; 68:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betterle C, Rossi A, Dalla Pria S, et al. Premature ovarian failure: autoimmunity and natural history. Clin Endocrinol (Oxf) 1993; 39:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakalov VK, Vanderhoof VH, Bondy CA, Nelson LM. Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure. Hum Reprod 2002; 17:2096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaBarbera AR, Miller MM, Ober C, Rebar RW. Autoimmune etiology in premature ovarian failure. Am J Reprod Immunol Microbiol 1988; 16:115.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7426 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3960433" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Incidence of premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10582785" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15950644" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Assessing the emotional needs of women with spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11978278" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11308110" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The lived experience of premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16645540" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15292326" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16221806" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Age at natural menopause and cause-specific mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17371475" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17761551" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24508665" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Oophorectomy, estrogen, and dementia: a 2014 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24945456" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28426619" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12117397" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10818427" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Premature ovarian failure is not premature menopause.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3012339" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Biologic effects of transdermal estradiol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19196677" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Clinical practice. Primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17309934" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15657326" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effect of estrogen therapy on gallbladder disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8569016" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24905063" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29039146" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20738314" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7962345" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19939372" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A prospective evaluation of antral follicle function in women with 46,XX spontaneous primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15866564" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : An update: spontaneous premature ovarian failure is not an early menopause.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28739117" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8855811" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17509587" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9159452" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cumulative conception and live birth rates after oocyte donation: implications regarding endometrial receptivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9532996" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Obstetric outcome in 232 ovum donation pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9557862" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Obstetric and perinatal outcome after oocyte donation: comparison with in-vitro fertilization pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10469693" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The influence of donated gametes on the incidence of hypertensive disorders of pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17727845" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Obstetric outcomes in donor oocyte pregnancies compared with advanced maternal age in in vitro fertilization pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2526032" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The effect of gonadotropin suppression on the induction of ovulation in premature ovarian failure patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24283158" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Idiopathic premature ovarian failure: what is the most suitable ovarian stimulation protocol?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1471696" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Gonadotropins enhance HLA-DR antigen expression in human granulosa cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2110073" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Ovulation induction and pregnancies in 100 consecutive women with hypergonadotropic amenorrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17261285" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1735500" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Ovulation induction in women with premature ovarian failure: a prospective, crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7615102" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Ovulation induction in premature ovarian failure: a placebo-controlled randomized trial combining pituitary suppression with gonadotropin stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10402388" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Treatment of autoimmune premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Spontaneous premature ovarian failure: young women, special needs
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17961560" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21127440" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Sexual function of women with premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9859027" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : High levels of serum allopregnanolone in women with premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15671097" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Ovarian steroidogenesis and serum androgen levels in patients with premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9015699" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Serum levels of androstenedione, testosterone and dehydroepiandrosterone sulfate in patients with premature ovarian failure to age-matched menstruating controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24473536" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19091633" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Management of premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17495481" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8348706" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Premature ovarian failure: autoimmunity and natural history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12151443" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3289410" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Autoimmune etiology in premature ovarian failure.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
